Aker BioMarine Antarctic receives no objection GRAS status for krill oil

August 15, 2011

Aker BioMarine Antarctic (Aker BM) has announced that the U.S. Food and Drug Administration (FDA) has accepted with no objections the notification of its independent GRAS determination for Superba krill oil for use as a food ingredient. This acceptance, plus the FDA's recent acknowledgement of Aker BM's New Dietary Ingredient Notification (NDIN), provides regulatory support for existing and prospective customers of "Consumer safety and trust is paramount in the natural ingredients arena, and Aker BioMarine Antarctic has developed an extensive safety dossier for Superba krill oil. The FDA's earlier acknowledgement of our NDIN was important for our existing and future customers to introduce Superba products in all supplement channels, while the new self-affirmed GRAS Notice acceptance solidly opens the door to applications in the food and beverage industries as well," said Matts Johansen, EVP Sales and Marketing.

The phospholipid-bound EPA and DHA present in Superba krill oil provide bioavailable omega-3 fatty acids for use in a number of food categories including beverages, cereals, cheese, and dairy products, as well as dietary supplements.

Press release

Story Tools